StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

by · The Cerbat Gem

Equities research analysts at StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ – Get Free Report) in a report issued on Monday. The firm set a “hold” rating on the medical research company’s stock.

Enzo Biochem Stock Performance

Shares of ENZ stock opened at $1.13 on Monday. The company has a 50 day moving average price of $1.12 and a 200 day moving average price of $1.12. Enzo Biochem has a fifty-two week low of $0.99 and a fifty-two week high of $1.50.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Enzo Biochem stock. XTX Topco Ltd lifted its stake in shares of Enzo Biochem, Inc. (NYSE:ENZ – Free Report) by 94.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,262 shares of the medical research company’s stock after buying an additional 13,735 shares during the quarter. XTX Topco Ltd owned about 0.05% of Enzo Biochem worth $31,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 36.90% of the company’s stock.

About Enzo Biochem

(Get Free Report)

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.

Featured Articles